Sanofi is negotiating a deal to sell a controlling stake in its Consumer Healthcare division enabling the French firm to retain a substantial share of the business.
Private Equity Poised To Take Control Of Opella But Sanofi Will Retain Sizable Stake
Control of Sanofi Consumer Healthcare – recently rebranded as Opella – may soon pass to US private-equity firm CD&R but the French firm looks set to retain a substantial stake in a business which has some big Rx-to-OTC switches in the pipeline.
More from Deals
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.
• By
Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.
• By
A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.
More from Business
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”